Computer-aided detection (CAD) developer Medicsight is planning a clinical studies program in China for its LungCAD and ColonCAD products.
A Chinese investigator team will lead the program, which will provide research to help improve Medicsight's CAD algorithms, according to the London-based firm. The Chinese team will collaborate with Medicsight's in-house clinical team in London, as well as two U.K. radiologists, Medicsight said.
In other Medicsight news, the firm has raised $7.5 million from a sale of 1.9 million shares of its common stock. The proceeds will be used to fund the firm's CAD software product initiatives, ongoing operations, and the acquisition of property and equipment.
By AuntMinnie.com staff writers
November 1, 2005
Related Reading
Medicsight, Viatronix partner, October 12, 2005
TeraRecon, Medicsight ally, August 19, 2005
Medicsight notches distribution trifecta, November 24, 2004
Copyright © 2005 AuntMinnie.com
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
